AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The company’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVir’s technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Founded date: 2013
Investors 1
| Date | Name | Website |
| - | EcoR1 Capi... | ecor1cap.c... |
Mentions in press and media 8
| Date | Title | Description | Source |
| 11.03.2024 | ALVR DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encour... | NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,... | einpresswi... |
| 22.12.2023 | The clock is ticking, and Cytokinetics is running out of Dec... | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech ne... | statnews.c... |
| 13.12.2021 | AlloVir : Announces Positive Preliminary Data from the Ongoi... | AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Preventi... | marketscre... |
| 22.03.2021 | AlloVir Appoints Diana M. Brainard, M.D., as Chief Executive... | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 22, 2021-- AlloVir (Nasdaq: ALVR), a late clinical-stage cell... | oaoa.com/n... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Figh... | Alain Mérieux, founder of BioMérieux.AFP via Getty Images | forbes.com... |
| 30.05.2019 | Houston biotech company closes $120M Series B, Chevron taps ... | Big things are happening in Houston — from a $120 million close to the U.S. Department of Energy pic... | houston.in... |
| 22.05.2019 | ElevateBio names AlloVir as its first portfolio company | Based in Houston, AlloVir is developing allogeneic cell therapies for viral diseases and is planning... | medcitynew... |
| - | ElevateBio names AlloVir as its first portfolio company | A company set up to take biomedical research from academia and build companies around it has reveale... | medcitynew... |